Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03034460
Other study ID # RD.03.SPR.109807
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 25, 2016
Est. completion date November 2, 2016

Study information

Verified date January 2017
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.


Description:

Study drugs application will be performed once daily, 5 days a week during 6 weeks


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date November 2, 2016
Est. primary completion date November 2, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: 1. The subject is a male or a female aged from 18 to 35 years old at screening visit. 2. The subject has a medical diagnosis of acne vulgaris : 2.1 at least 20 (twenty) inflammatory lesions and a maximum of 100 (one hundred) non-inflammatory lesions (nose is excluded for the lesion count) at Baseline 2.2 symmetry of the lesions: No more than twice as many acne lesions on one side as compared to the other side at Baseline 3. If the subject is a female of childbearing potential, she must agree to use an effective contraceptive method for the duration of the study Exclusion Criteria: 1. The subject has an underlying known disease surgical or medical condition, in the opinion of the investigator might interfere with interpretation of the study results or put the subject at risk (e.g., other dermatological diseases affecting the treatment area, such as a dermatitis, eczema, etc., or any uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study, such as a cancer, leukemia or severe hepatic impairment), (Screening). 2. The subject has acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, or acne requiring systemic treatment. 3. The subject has a known or suspected allergies or sensitivities to any components of any of the study drugs (see Investigator's Brochure/Product label). 4. The subject is a male with beard or facial hair, which would interfere with clinical evaluation or clinical procedure (Screening and Baseline).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CD5024 1% cream
500 µL on half-face, five days a week during 6 weeks
CD5024 cream placebo
500 µL on half-face, five days a week during 6 weeks
CD0271/CD1579 gel
500 µL on half-face, five days a week during 6 weeks
CD0271/CD1579 gel placebo
500 µL on half-face, five days a week during 6 weeks

Locations

Country Name City State
Canada Galderma Investigational site Montreal Quebec
Canada Galderma Investigational Site (# 8060) Windsor Ontario
France Galderma investigational site Nantes
France Galderma investigational site Nice
Germany Galderma investigational site Berlin
Germany Galderma investigational site Bochum
Germany Galderma investigational site Munster

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Countries where clinical trial is conducted

Canada,  France,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Inflammatory Lesion Count (Papules and Pustules) at Day 40 Inflammatory lesion count corresponded to the sum of papules and pustules. Day 40
Secondary Inflammatory Lesion Count (Papules and Pustules) at Baseline (Day 1) Inflammatory lesion count corresponded to the sum of papules and pustules. Baseline (Day 1)
Secondary Percent Reduction From Baseline (Day 1) in Inflammatory Lesion Count at Day 40 Inflammatory lesion count corresponded to the sum of papules and pustules. Baseline (Day 1), and Day 40
Secondary Total Lesion Count at Baseline (Day 1) and Day 40 Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules. Baseline (Day 1), and Day 40
Secondary Percent Reduction From Baseline (Day 1) in Total Lesions at Day 40 Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules. Baseline (Day 1), and Day 40
Secondary Non-Inflammatory Lesion Count at Baseline (Day 1) and Day 40 Non-inflammatory lesion counts corresponded to the sum of open and closed comedones. Baseline (Day 1), and Day 40
Secondary Percent Reduction From Baseline in Non-Inflammatory Lesion at Day 40 Non-inflammatory lesion counts corresponded to the sum of open and closed comedones. Baseline (Day 1), and Day 40
Secondary Number of Participants Reported for Investigator's Preference on a 5-Point Scale at Day 40 The Investigator gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side. Day 40
Secondary Number of Participants Reported for Participant's Preference on 5-Point Scale at Day 40 The participants gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side. Day 40
Secondary Number of Participants With Adverse Events (AEs) AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily had a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. From start of study up to follow up (Week 7)
Secondary Number of Participants Reported Worst Local Tolerability Score on Treated Areas (Face and Ear) From Day 1 to Follow up (Week 7) Signs and symptoms of local cutaneous irritation(local tolerability [erythema, scaling, dryness, stinging/burning, pruritus]) were evaluated on all treated areas (face and behind ears if applicable) every day from Day 1 up to follow-up (Week 7) using a 4-point scale of None (0), Mild (1), Moderate (2), or Severe (3). Number of participants reported worst local tolerability score on treated areas from Day 1 to follow up (Week 7) was reported. From Day 1 up Follow up (Week 7)
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT04806594 - Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar. N/A
Recruiting NCT03465150 - Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
Completed NCT02250859 - A Pharmacokinetic Study of Minocycline in Male and Female Volunteers Phase 1
Completed NCT01206348 - Combination Treatment for Moderate to Severe Acne Phase 4
Terminated NCT01193764 - Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris N/A
Completed NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne Phase 2
Completed NCT05640388 - Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Completed NCT04873089 - Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
Recruiting NCT05941065 - Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin N/A
Recruiting NCT06120452 - A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation N/A
Completed NCT04300010 - Blue Light Therapy of C. Acnes Phase 4
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT04559022 - Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring N/A
Terminated NCT02431494 - Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris N/A
Completed NCT05469880 - Efficacy and Tolerance of Formula 609613 37 in Acneic Patients N/A
Completed NCT02944461 - Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Phase 4
Completed NCT01951417 - Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Phase 4
Completed NCT01701024 - Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne Phase 3